The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Splicing inhibitors

Splicing inhibitors

Inhibiting the spliceosome may have clinical benefit to patients with spliceosomal gene mutations. Existing sulfonamide drugs may be able to target certain RNA-binding proteins in spliceosome-mutant AML.

| |

All Interventions